Anbio Biotechnology (NNNN) Cash & Current Investments (2023 - 2025)
Anbio Biotechnology has reported Cash & Current Investments over the past 3 years, most recently at $11.9 million for Q4 2025.
- Quarterly results put Cash & Current Investments at $11.9 million for Q4 2025, up 1.19% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (up 1.19% YoY), and the annual figure for FY2025 was $11.9 million, up 1.19%.
- Cash & Current Investments for Q4 2025 was $11.9 million at Anbio Biotechnology, up from $11.8 million in the prior quarter.
- Over the last five years, Cash & Current Investments for NNNN hit a ceiling of $11.9 million in Q4 2025 and a floor of $9.7 million in Q4 2023.
- Median Cash & Current Investments over the past 3 years was $11.8 million (2024), compared with a mean of $11.1 million.
- Biggest five-year swings in Cash & Current Investments: grew 21.36% in 2024 and later increased 1.19% in 2025.
- Anbio Biotechnology's Cash & Current Investments stood at $9.7 million in 2023, then increased by 21.36% to $11.8 million in 2024, then grew by 1.19% to $11.9 million in 2025.
- The last three reported values for Cash & Current Investments were $11.9 million (Q4 2025), $11.8 million (Q4 2024), and $9.7 million (Q4 2023) per Business Quant data.